Comparison Overview
Philips Pharma Solutions, formerly BioTel Research
Philips Pharma Solutions, formerly BioTel Research
155 Corporate Woods, Suite 180, Rochester, New York, US, 14623
Last Update: 03/04/2026
Philips Pharma Solutions, formerly BioTel Research, is a leading central core lab supporting clinical trials with products, services, and technologies for cardiac monitoring, medical imaging, and remote data capture. It was acquired by ICON plc in October 2023.
Alembic Pharmaceuticals Limited
Alembic Road, Vadodara, 390003, IN
Last Update: 01/04/2026
Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is t...
Compliance Ranges Comparison
Philips Pharma Solutions, formerly BioTel Research
Alembic Pharmaceuticals Limited
Benchmark & Cyber Underwriting Signals
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for Philips Pharma Solutions, formerly BioTel Research in 2026.
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for Alembic Pharmaceuticals Limited in 2026.
Incident History - Philips Pharma Solutions, formerly BioTel Research (X = Date, Y = Severity)
Philips Pharma Solutions, formerly BioTel Research cyber incidents detection timeline including parent company and subsidiaries.
Incident History - Alembic Pharmaceuticals Limited (X = Date, Y = Severity)
Alembic Pharmaceuticals Limited cyber incidents detection timeline including parent company and subsidiaries.
Notable Incidents
Philips Pharma Solutions, formerly BioTel Research
Alembic Pharmaceuticals Limited
FAQ
Latest Global CVEs
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an inadequate encryption strength vulnerability which could allow an attacker to steal admin credentials via weak hash or a pass-the-hash attack.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an exposure of sensitive system information to an unauthorized control sphere vulnerability which could allow for asset discovery by unauthenticated users.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an unintended proxy or intermediary vulnerability which could allow an attacker to use an active proxy, which would bypass OT segmentation.
Pronetiqs IntraVUE Versions 3.2.1a14 and prior have a plaintext storage of a password vulnerability that could expose cleartext credentials through the API.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an exposure of sensitive system information to an unauthorized control sphere vulnerability which could expose the underlying host/share filesystem.